TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03224143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doll Therapy Intervention
Description: Daily sessions, lasting an hour, will take place in a room known to patients (P). The only people in the room will be a nurse (N) and the researcher with video-tape, never interacting with P. The procedure is: the N will accompany the P in the room and the P will take a seat. The N will put the doll in front of the P and will say Good morning Mr./Mrs....look, with a quiet voice. If the P will not take it at the first attempt, the N will sit down in front of her holding the doll in the arms and will wait for 2 minutes. The N will invite the PWD again. If the P will not take the doll after the second request, the N will not insist and she will leave. If the doll will be taken, the N will leave the P and say I have to go, goodbye Mr./Mrs. . . ... The gaze will always be upon the P.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: active control group (SI)
Description: Daily sessions, lasting an hour, will take place in a room known to patients (P). The only people in the room will be a nurse (N) and the researcher with video-tape, never interacting with P. The procedure is: the N will accompany the P in the room and the P will take a seat. The N will put the cube in front of the P and will say Good morning Mr./Mrs....look, with a quiet voice. If the P will not take it at the first attempt, the N will sit down in front of her holding the cube in the arms and will wait for 2 minutes. The N will invite the PWD again. If the P will not take the cube after the second request, the N will not insist and she will leave. If the cube will be taken, the N will leave the P and say I have to go, goodbye Mr./Mrs. . . ... The gaze will always be upon the P.
Study: NCT00510393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus eluting coronary stent system

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MULTILINK VISION coronary stent system
Study: NCT04261374

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of sublingual microcirculation
Description: Measurement of sublingual microcirculation
Study: NCT00337493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil [CellCept]
Description: Concentration-controlled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil [CellCept]
Description: Concentration-controlled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil [CellCept]
Description: 1g po bid
Study: NCT04447781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA® 2000
Description: - Manufacturer: Inovio Pharmaceuticals Inc.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA® 2000
Description: - Manufacturer: Inovio Pharmaceuticals Inc.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA® 2000
Description: - Manufacturer: Inovio Pharmaceuticals Inc.
Study: NCT00337493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine or tacrolimus
Description: Reduced

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine or tacrolimus
Description: Standard, as prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine or tacrolimus
Description: Standard, as prescribed
Study: NCT04447781

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CELLECTRA® 2000
Description: - Manufacturer: Inovio Pharmaceuticals Inc.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline-sodium citrate (SSC) buffer
Description: - Manufacturer: Inovio Pharmaceuticals Inc.
Study: NCT03658629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NanoFlu (Quad-NIV)
Description: 2018-2019 Investigational Quadrivalent Seasonal Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NanoFlu (Quad-NIV)
Description: 2018-2019 Investigational Quadrivalent Seasonal Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NanoFlu (Quad-NIV)
Description: 2018-2019 Investigational Quadrivalent Seasonal Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NanoFlu (Quad-NIV)
Description: 2018-2019 Investigational Quadrivalent Seasonal Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NanoFlu (Quad-NIV)
Description: 2018-2019 Investigational Quadrivalent Seasonal Influenza Vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matrix-M Adjuvant
Description: Adjuvant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matrix-M Adjuvant
Description: Adjuvant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matrix-M Adjuvant
Description: Adjuvant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matrix-M Adjuvant
Description: Adjuvant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone HD
Description: 2018-2019 Licensed Trivalent Seasonal Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flublok Quadrivalent
Description: 2018-2019 Licensed Quadrivalent Seasonal Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: 2018-19 Licensed Seasonal Influenza Vaccine
Study: NCT04435730

Intervention type: DIAGNOSTIC_TEST
Intervention: serum level of Mac 2 binding protein
Description: Serum levels of Mac 2 binding protein will be measured for all the study subjects using Enzyme-Linked Immuno sorbent Assay (ELISA).~2 ml of venous blood will be collected from patients and controls under complete aseptic conditions in a plain tube. Sample will be allowed to clot for 15-30 min at room temperature and then centrifuged at 2500 rpm for 10-15 min. Serum will be separated and stored at -20 C or lower till time of assessment.

Intervention type: DIAGNOSTIC_TEST
Intervention: serum level of Mac 2 binding protein
Description: Serum levels of Mac 2 binding protein will be measured for all the study subjects using Enzyme-Linked Immuno sorbent Assay (ELISA).~2 ml of venous blood will be collected from patients and controls under complete aseptic conditions in a plain tube. Sample will be allowed to clot for 15-30 min at room temperature and then centrifuged at 2500 rpm for 10-15 min. Serum will be separated and stored at -20 C or lower till time of assessment.

Intervention type: DIAGNOSTIC_TEST
Intervention: serum level of Mac 2 binding protein
Description: Serum levels of Mac 2 binding protein will be measured for all the study subjects using Enzyme-Linked Immuno sorbent Assay (ELISA).~2 ml of venous blood will be collected from patients and controls under complete aseptic conditions in a plain tube. Sample will be allowed to clot for 15-30 min at room temperature and then centrifuged at 2500 rpm for 10-15 min. Serum will be separated and stored at -20 C or lower till time of assessment.
Study: NCT03280927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jublia®
Description: Jublia® topical solution
Study: NCT01110070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChonDux
Description: Comparison of ChonDux plus microfracture to microfracture only
Study: NCT04435730

Intervention type: DIAGNOSTIC_TEST
Intervention: serum level of Mac 2 binding protein
Description: Serum levels of Mac 2 binding protein will be measured for all the study subjects using Enzyme-Linked Immuno sorbent Assay (ELISA).~2 ml of venous blood will be collected from patients and controls under complete aseptic conditions in a plain tube. Sample will be allowed to clot for 15-30 min at room temperature and then centrifuged at 2500 rpm for 10-15 min. Serum will be separated and stored at -20 C or lower till time of assessment.

Intervention type: DEVICE
Intervention: musculoskeletal ultrasound
Description: MSUS examination will be performed for patients of all groups and control group.Gray scale (GSUS) and power Doppler (PDUS) at joints levels and entheses will be performed with the same transducer of My Lab Seven Crystalline esaote machine.

Intervention type: DEVICE
Intervention: musculoskeletal ultrasound
Description: MSUS examination will be performed for patients of all groups and control group.Gray scale (GSUS) and power Doppler (PDUS) at joints levels and entheses will be performed with the same transducer of My Lab Seven Crystalline esaote machine.

Intervention type: DEVICE
Intervention: musculoskeletal ultrasound
Description: MSUS examination will be performed for patients of all groups and control group.Gray scale (GSUS) and power Doppler (PDUS) at joints levels and entheses will be performed with the same transducer of My Lab Seven Crystalline esaote machine.

Intervention type: DEVICE
Intervention: musculoskeletal ultrasound
Description: MSUS examination will be performed for patients of all groups and control group.Gray scale (GSUS) and power Doppler (PDUS) at joints levels and entheses will be performed with the same transducer of My Lab Seven Crystalline esaote machine.
Study: NCT02403531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: definitive radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: definitive radiotherapy
Study: NCT02909101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Cognitive Training (ACT)
Description: Cognitive training games

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control Training (CON)
Description: Cognitive training games
Study: NCT06325943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Patients will receive two doses of rituximab 1 g at two-week interval and one dose of rituximab 1 g at month 6

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive two doses of placebo at two-week interval and one dose of placebo at month 6
Study: NCT03174795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7079901
Description: Participants will receive RO7079901 2000 milligrams (mg) IV treatment, three times a day (TID) for up to 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: Participants will receive meropenem 2000 mg IV treatment TID for up to 14 days.
Study: NCT04504084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: Patient Decision Aid is a tool that helps patient with ureteral stone become involved in decision making on choosing treatment for ureteral stone. Patient Decision Aid provides information about the options and outcomes, and by clarifying personal values.
Study: NCT03202875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR341402
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT03240432

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom CGM
Description: CGM group will be instructed on how to utilize the CGM data for diabetes management. Participants will be encouraged to use CGM values for making diabetes management decisions and will be provided guidelines for when to confirm with a study BGM fingerstick.
Study: NCT05118438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion Nursing Intervention
Description: A one-on-one program was conducted over six sessions, with each session ranging from 60 to 120 minutes. The caring program for health promotion included the following concepts: understanding the self; sharing traumatic events and negative emotions; re-framing the meaning of traumatic events; identifying thoughts and physical and emotional responses; developing health-promoting activities; and maintaining a positive attitude during the process of change .
Study: NCT03644446

Intervention type: BIOLOGICAL
Intervention: Bisoprolol plasma residual concentration dosage
Description: Bisoprolol plasma residual concentration dosage will be subsequently studied by renal function (altered if creatinine clearance \< 30mL/min, mild altered between 30-60mL/min, normal \> 60mL/min as estimated by the CKD-EPI formula)

Intervention type: BIOLOGICAL
Intervention: Bisoprolol plasma residual concentration dosage
Description: Bisoprolol plasma residual concentration dosage will be subsequently studied by renal function (altered if creatinine clearance \< 30mL/min, mild altered between 30-60mL/min, normal \> 60mL/min as estimated by the CKD-EPI formula)

Intervention type: BIOLOGICAL
Intervention: Bisoprolol plasma residual concentration dosage
Description: Bisoprolol plasma residual concentration dosage will be subsequently studied by renal function (altered if creatinine clearance \< 30mL/min, mild altered between 30-60mL/min, normal \> 60mL/min as estimated by the CKD-EPI formula)
Study: NCT04299425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRAF Detection Technology
Description: Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).~After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio \> 1.2 is interpreted by device as the suspect tissue being positive for parathyroid.
Study: NCT02271919

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine Lozenge
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine Patch
Description: Given via patch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO or via patch

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO or via patch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Receive behavioral smoking cessation counseling

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tobacco Cessation Counseling
Description: Receive behavioral smoking cessation counseling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Given PO
Study: NCT03496025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation
Description: The intervention consists of activating paralyzed facial muscles with electrical stimulation.
Study: NCT02344303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00951561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vipon
Description: The Vipon is a tampon with a small motor unit within, which produces vibratory stimulation, used during menstruation to provide pain relief for women with dysmenorrhea.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 400 mg daily
Study: NCT02092987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social work support
Description: All study participants were provided access to social support services at Riverstone Senior Life services

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social work support
Description: All study participants were provided access to social support services at Riverstone Senior Life services

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational material
Description: All participants received educational material about dementia and caregiving in addition to information about resources for persons with dementia and their caregivers, including resources at the Alzheimer's Association such as support groups, and clinical and service resources available citywide.
Study: NCT02138110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro-Spinal Scaffold
Description: Implantation of a Neuro-Spinal Scaffold into the epicenter of the post-irrigation contusion cavity during open spine surgery
Study: NCT02092987

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational material
Description: All participants received educational material about dementia and caregiving in addition to information about resources for persons with dementia and their caregivers, including resources at the Alzheimer's Association such as support groups, and clinical and service resources available citywide.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NYU caregiver counseling intervention
Description: The first component consists of 2 individual and 4 family counseling sessions. These sessions last between 1 and 1.5 hours. The second component of the intervention is participation in a caregiver support group . The third component of the treatment is ad hoc counseling. New psychiatric and behavioral problems of patients, which are generally more stressful than the need for assistance with activities of daily living or physical limitations, often precipitate ad hoc calls from caregivers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: REACH OUT counseling intervention
Description: All aspects of the REACH OUT Intervention involve problem solving techniques and the development of written action plans. The goal of this intervention is to engage the caregiver in joint problem-solving with the objective of creating a written action plan targeting specific caregiving problems. The basic steps of problem solving are: 1.Define the problem. 2. Set goals 3. Brainstorm with caregiver and List possible solutions on a pad of paper, 4. Select solutions, 5. Develop an action plan based on these solutions, 6. Implement the action plan, track progress, and make adjustments as needed
Study: NCT02189863

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B MF
Description: Multifocal contact lenses worn in both eyes

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B MF
Description: Multifocal contact lenses worn in both eyes

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B MV
Description: Spherical contact lenses worn with 1 eye corrected for distance and 1 eye corrected for near

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B MV
Description: Spherical contact lenses worn with 1 eye corrected for distance and 1 eye corrected for near

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B SVD
Description: Spherical contact lenses worn with both eyes corrected for distance

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B SVD
Description: Spherical contact lenses worn with both eyes corrected for distance

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A MF
Description: Multifocal contact lenses worn in both eyes
Study: NCT00427388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given by IV in 2 doses (250 mg each dose for a total of 500 mg)
Study: NCT01888198

Intervention type: BEHAVIORAL
Intervention: (EORTC QLQ-C30) questionnaire

Intervention type: BEHAVIORAL
Intervention: EuroQol EQ-5D 7-item questionnaire
Study: NCT00427388

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given in 2 IV doses (approximately 4 ml of 0.9% normal saline solution in each dose)
Study: NCT04034979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: decision aid
Description: One hour online training about shared-decision making about goals-of-care and best practices regarding goals-of-care discussions and decision-making. One hour debriefing in presence.
Study: NCT01110070

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ChonDux
Description: Comparison of ChonDux plus microfracture to microfracture only

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ChonDux
Description: single use device
Study: NCT02424214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Oocyte activation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Oocyte activation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ca Ionophore

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Strontium Chloride
Study: NCT03312751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emapalumab
Description: Emapalumab will be administered by intravenous infusion, twice weekly.
Study: NCT00375947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham hand cream
Description: placebo intervention
Study: NCT02402842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Cisplatin and 5-Fluorouracil
Description: Patients will receive 6 cycles of DCF regimen (docetaxel 75 mg/m2 day, cisplatin 75 mg/m2 and 5 Fluorouracil at 750 mg/m2/day for 5 days) every 3 weeks or 8 cycles of modified-DCF regimen (docetaxel 40 mg/m2 day, cisplatin 40 mg/m2 day and 5-Fluorouracil at 1200 mg/m2/day for 2 days) every 2 weeks, according to their clinical status.
Study: NCT00442468

Intervention type: OTHER
Intervention: Non-interventional study.
Description: This is a non-interventional (no drug treatment administered), prevalence (observational) study.